Evidence map›Paper›PMID 39747852›Full record

ArticleScientific reports2025

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Hideko OhamaGastroenterology Center, Ehime Prefectural Central Hospital, 83, Kasuga-Machi, Matsuyama, Ehime, 790-0024, Japan.
Atsushi HiraokaGastroenterology Center, Ehime Prefectural Central Hospital, 83, Kasuga-Machi, Matsuyama, Ehime, 790-0024, Japan. hirage@m.ehime-u.ac.jp.
Toshifumi TadaDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Masashi HirookaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kazuya KariyamaDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Shinya FukunishiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kunihiko TsujiCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Toru IshikawaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Kazuto TajiriDepartment of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Hironori OchiCenter for Liver- Biliary- Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Satoshi YasudaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Chikara OgawaDepartment of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Takashi NishimuraDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Satoru KakizakiDepartment of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
Noritomo ShimadaDivision of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.
Hisashi KosakaDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Tomomitsu MatonoDepartment of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan.
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan.
Yutaka YataDepartment of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
Hironori TanakaDepartment of Gastroenterology, Takarazuka City Hospital, Hyogo, Japan.
Hiroki NishikawaDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Hiroshi ShibataDepartment of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Fujimasa TadaGastroenterology Center, Ehime Prefectural Central Hospital, 83, Kasuga-Machi, Matsuyama, Ehime, 790-0024, Japan.
Kazuhiro NousoDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
Akemi TsutsuiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Takuya NaganoDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Norio ItokawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Tomomi OkuboDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Taeang AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Michitaka ImaiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Yohei KoizumiDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Shinichiro NakamuraDepartment of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
Hiroko IijimaDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Masaki KaiboriDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Takashi KumadaDepartment of Nursing, Gifu Kyoritsu University, Ogaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesAgedAged, 80 and overAntineoplastic AgentsFemaleGeriatric AssessmentHumansMaleMiddle AgedNutritional StatusNutrition AssessmentPrognosisProgression-Free SurvivalAntineoplastic AgentslenvatinibPhenylurea CompoundsQuinolinesCRPGNRIGNRI-CHepatocellular carcinomaLenvatinib

Identifiers

PMID39747852
PMCPMC11696502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.